ALX Oncology Holdings Inc (ALXO)
1.29
-0.04
(-3.01%)
USD |
NASDAQ |
Nov 15, 16:00
1.29
0.00 (0.00%)
After-Hours: 20:00
ALX Oncology Holdings Net Income (TTM): -151.16M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | -151.16M |
| June 30, 2024 | -171.44M |
| March 31, 2024 | -166.20M |
| December 31, 2023 | -160.80M |
| September 30, 2023 | -146.04M |
| June 30, 2023 | -130.37M |
| March 31, 2023 | -129.13M |
| December 31, 2022 | -123.48M |
| September 30, 2022 | -121.21M |
| June 30, 2022 | -110.46M |
| Date | Value |
|---|---|
| March 31, 2022 | -93.81M |
| December 31, 2021 | -83.46M |
| September 30, 2021 | -73.80M |
| June 30, 2021 | -59.41M |
| March 31, 2021 | -54.47M |
| December 31, 2020 | -45.74M |
| September 30, 2020 | -34.73M |
| June 30, 2020 | -27.59M |
| March 31, 2020 | -20.46M |
| December 31, 2019 | -19.24M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-171.44M
Minimum
Jun 2024
-19.24M
Maximum
Dec 2019
-96.15M
Average
-102.13M
Median
Net Income (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 322.29M |
| Neurocrine Biosciences Inc | 385.90M |
| Eton Pharmaceuticals Inc | -6.687M |
| Verve Therapeutics Inc | -197.03M |
| Immuneering Corp | -56.07M |